Genetic Basis for Variation in the Renal Elimination of Metformin

Phase 4 Completed 23 enrolled University of California, San Francisco

Non-randomizedParallel-groupOpen-label

Summary

The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. We will study individuals with particular genotypes of the human organic cation transporter, (hOCT2), to test the hypothesis that genetic variation in hOCT2 is associated with variation in the renal clearance of the antidiabetic agent, metformin.

Timeline

Start: 2002-05
Primary completion: 2008-04
Completion: 2008-04

Publications

Results Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee SW, Choi JH, Huang Y, Brett CM, Burchard EG, Giacomini KM. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics. 2009 Jul;19(7):497-504. doi: 10.1097/FPC.0b013e32832cc7e9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metformin	Small molecule	850 mg	Oral

Indications

No indication recorded.